Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 17/20 | 0.83 |
| ▸ | RARB | P10826 | 16/20 | 0.83 |
| ▸ | RARA | P10276 | 15/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382609 | 0.95 | RARG (0.82) | RARGRARBRARAEGFRKDM4E | |
| SCHEMBL382160 | 0.91 | RARG (0.81) | RARGRARBRARA | |
| SCHEMBL382479 | 0.91 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL381872 | 0.89 | RARG (0.80) | RARGRARBRARA | |
| SCHEMBL382843 | 0.88 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL381961 | 0.86 | RARG (0.80) | RARGRARBRARA | |
| Trifarotene SCHEMBL381493 | 0.86 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL27337609 | 0.86 | RARG (0.85) | RARGRARBRARA | |
| SCHEMBL382599 | 0.86 | RARG (0.78) | RARGRARBRARA | |
| SCHEMBL382355 | 0.86 | RARG (0.80) | RARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831149-B1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-01-25 | — | — | EP | disclosed |